March 2020 Appendix 4C and Quarterly Report
- Exopharm is now a clinical stage company, and the first company in the world to test a proprietary exosome product in human clinical trials, for regenerative medicine, with first dosing of PlexarisTM occurring in Exopharm's PLEXOVAL Study during the quarter
- Planning for the first-in-human allogeneic Plexaris safety study is progressing, however the PLEXOVALI study has been affected by the COVID-19 situation
- BioMAP external testing validates possible safety and mechanism of action
- Independent testing by PELVIPHARMshows potency of Cevaris in models of erectile dysfunction, and provides a basis for further testing, and future potential clinical trials in post-operative erectile dysfunction
- Positive PELVIPHARM testing provides a basis for further testing, and future potential clinical trials in urinary bladder control
- Exopharm consolidates main laboratory and manufacturing facility at the Baker Institute in Melbourne
http://exopharm.com/wp-content/uploads/2020/04/73._20.04.24-March-20-Quarterly-Reports-David-Parker.pdf
- Forums
- ASX - By Stock
- TYP
- Buy Recommendation
Buy Recommendation, page-71
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TYP (ASX) to my watchlist
|
|||||
Last
2.1¢ |
Change
-0.001(4.55%) |
Mkt cap ! $22.87M |
Open | High | Low | Value | Volume |
2.2¢ | 2.2¢ | 2.1¢ | $4.354K | 203.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 1202944 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.1¢ | 104 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 1202944 | 0.020 |
8 | 1307398 | 0.019 |
5 | 682509 | 0.018 |
1 | 500000 | 0.017 |
3 | 1058231 | 0.016 |
Price($) | Vol. | No. |
---|---|---|
0.021 | 104 | 1 |
0.022 | 930652 | 3 |
0.023 | 403477 | 3 |
0.024 | 40529 | 1 |
0.025 | 721144 | 4 |
Last trade - 10.15am 03/09/2024 (20 minute delay) ? |
Featured News
TYP (ASX) Chart |